Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity

Am J Cardiol. 2022 Jul 15:175:182-184. doi: 10.1016/j.amjcard.2022.04.030. Epub 2022 May 19.
No abstract available

Publication types

  • Letter
  • Meta-Analysis

MeSH terms

  • Glucagon-Like Peptides* / adverse effects
  • Humans
  • Obesity* / drug therapy
  • Overweight* / drug therapy

Substances

  • semaglutide
  • Glucagon-Like Peptides